Observational studyClinical and experimental nephrology2025
SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment.
Observational study in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis.Renal failure · 2026Article
- Magnesium and blood pressure regulation: systemic and renal mechanisms.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Verification of the Short-term Effect of SGLT2 Inhibitors on Serum Magnesium Stratified by the Classification of Albuminuria Severity in Patients with Type 2 Diabetes Mellitus.Internal medicine (Tokyo, Japan) · 2026Article
- Diabetes-induced Multiorgan Damage: Can Magnesium Delay the process?Current nutrition reports · 2026Review
- Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional StudyEndocrine, metabolic & immune disorders drug targets · 2026Article
- The Relationship Between Magnesium Depletion Score and Kidney Stone Risk in Gout Patients: a Mediation Analysis.Biological trace element research · 2025Article
- Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer.Clinical and experimental nephrology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown in clinical trials to increase serum Mg
methodsOur retrospective observational study included the 62 patients with CKD who started SGLT2 inhibitor therapy at our institution between 2017 and 2022 and who had complete data on serum Mg
resultsMedian eGFR and mean serum Mg
conclusionsSGLT2 inhibitors increased serum Mg
Indexed as
Identifiers
39549108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.